NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

RADNOR, Pa., April 8, 2024. NRx Pharmaceuticals, Inc. ( " NRx Pharmaceuticals " , the " Company " ), a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials